Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Liver Int. 2011 Oct;31(9):1366-72. doi: 10.1111/j.1478-3231.2011.02572.x. Epub 2011 Jun 28.
BACKGROUND & AIMS: Hepatitis B or C virus infection is considered to be the main cause of hepatocellular carcinoma (HCC) in Japan. Aflatoxin B1 (AFB1) is a carcinogen associated with HCC in regions with high exposure. Mutations in codon 249, exon 7 are a hallmark of AFB1 exposure. Therefore, to clarify the role of AFB1 in hepatocarcinogenesis, we examined AFB1-DNA in liver tissue and sequenced TP53 in Japanese patients with HCC.
Hepatocyte AFB1-DNA adducts were determined immunohistochemically and direct sequencing of TP53 was done to determine mutations in 188 of 279 patients who underwent hepatic resection for HCC. We assessed hepatitis C virus antibodies (HCV Ab) and HBSAg expression; patients without either were defined as having non-B non-C hepatocellular carcinoma (NBNC HCC).
AFB1-DNA adducts were detected in hepatocyte nuclei in 18/279 patients (6%), including 13/83 patients (16%) with NBNC HCC and 5/51 patients (10%) expressing hepatitis B surface antigen. None of the patients with HCV Ab (n=136) were positive for AFB1-DNA. The incidence of the G-T transversion and mutations in exon 7 of TP53 in patients with AFB1-DNA adducts were significantly higher in patients with than in patients without AFB1-DNA adducts. All three patients with the codon 249 AGG-AGT mutation had AFB1-DNA adducts.
Although exposure to AFB1 is thought to be low in Japan, it is still associated with hepatocarcinogenesis, particularly in NBNC HCC and hepatitis B individuals.
乙型肝炎或丙型肝炎病毒感染被认为是日本肝细胞癌(HCC)的主要病因。黄曲霉毒素 B1(AFB1)是与高暴露地区 HCC 相关的致癌物质。密码子 249 外显子 7 的突变是 AFB1 暴露的标志。因此,为了阐明 AFB1 在肝癌发生中的作用,我们检测了日本 HCC 患者肝组织中的 AFB1-DNA,并对 279 例接受肝切除术的 HCC 患者中的 188 例进行了 TP53 的直接测序。
通过免疫组织化学法检测肝细胞 AFB1-DNA 加合物,并对 188 例接受 HCC 肝切除术的患者进行 TP53 直接测序。我们评估了丙型肝炎病毒抗体(HCV Ab)和 HBSAg 表达;无两者的患者被定义为非乙型肝炎非丙型肝炎肝细胞癌(NBNC HCC)。
在 279 例患者中的 18 例(6%)肝细胞核中检测到 AFB1-DNA 加合物,包括 83 例 NBNC HCC 患者中的 13 例(16%)和 51 例乙型肝炎表面抗原表达患者中的 5 例。无 HCV Ab(n=136)的患者均为 AFB1-DNA 阳性。AFB1-DNA 加合物阳性患者的 G-T 颠换和 TP53 外显子 7 突变的发生率明显高于无 AFB1-DNA 加合物阳性患者。所有 3 例密码子 249 AGG-AGT 突变患者均有 AFB1-DNA 加合物。
尽管日本认为 AFB1 的暴露水平较低,但它仍与肝癌发生有关,尤其是在 NBNC HCC 和乙型肝炎个体中。